3results about How to "Minimize side effects" patented technology

This invention provides a lithium secondary battery, comprising: a battery casing; an electrode assembly housed within the battery casing; and an electrolyte, wherein the electrode assembly includes a positive electrode comprising a positive electrode active material, a separator, and a negative electrode comprising a negative electrode active material, and the electrolyte comprises LiPF6 as a lithium salt and ethylene carbonate as an organic solvent, wherein the ratio of the diameter (r) to the height (h) of the battery casing of the lithium secondary battery (shape factor ratio) is 0.4 or more, and satisfies the condition of mathematical formula (1), wherein in mathematical formula (1), h is the height (mm) of the battery casing, r is the diameter (mm) of the battery casing, and W LiPF6 The amount of LiPF6 relative to the total weight of the electrolyte, expressed as a percentage (%), W EC It is the amount of ethylene carbonate relative to the total weight of the electrolyte, expressed as a percentage (%), and W EL This represents the total weight (g) of the electrolyte contained in the lithium secondary battery. [Mathematical formula (1)]

This invention relates to the use of peptides as therapeutic agents for degenerative brain diseases. Specifically, it confirms that the peptides of this invention, by targeting microglia, induce microglia in an inflammatory state to an anti-inflammatory state in a disease environment, thereby reducing neuroinflammation and enhancing phagocytic function to clear amyloid-β. Furthermore, in animal models of degenerative brain diseases, the effects of reducing amyloid-β, restoring synaptic plasticity, and improving cognitive impairments related to anxiety, learning, and memory have been confirmed. Therefore, the peptides of this invention can be effectively used as active ingredients in compositions for the prevention or treatment of degenerative brain diseases and the resulting cognitive, learning, or memory impairments.

The present invention provides a dispersion composition comprising: a dispersion medium; and particles comprising a target substance. The dispersion composition comprises at least one surfactant at a concentration above the critical micelle concentration, and does not comprise a solubilizer. The target substance is cyclosporin A, and satisfies the previously defined S-parameter > 1.